The Safety of Paclitaxel in Treating Peripheral Artery Disease
The Eluvia Drug-Eluting Vascular Stent System




Lowest Amount of Paclitaxel
The Eluvia stent has only 1/3 of the total drug dose compared to a competitor's peripheral drug-coated stent. The drug dose density is also approximately 18x lower.6,7


A Unique Mechanism for Delivery
The only peripheral stent approved by the FDA that has a polymer, which controls how and when the drug is released. The polymer matrix – studied in more than 100,000 patients in clinical trials and implanted in more than 20 million vessels – plays a critical role in coating integrity and stability and further enhances the safety of Eluvia.8,9
A Controlled Distribution of Paclitaxel
The low-dose drug on the Eluvia stent is released in a controlled manner – initially at the time of implantation and then sustained through a gradual release over the course of several months to prevent re-narrowing of the artery.


Safety Information about Boston Scientific Devices
Patient safety is our priority and our constant focus. Read more about how we monitor the safety of all of our devices.

Peripheral Artery Disease
PAD is a cardiovascular disease in which narrowed arteries reduce blood flow to the limbs. Read more about the causes of PAD, risk factors and treatment options available.
Still Have Questions?
For more information on the Eluvia Stent, please contact
Boston Scientific customer service at 1-888-272-1001.
- Data on file at Boston Scientific.
- Stone GW, Ellis SG, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4(5):530-542.
- Ormiston JA, Charles O, Mann T, et al. Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberte paclitaxel-eluting stent in de-novo coronary artery lesions. Coron Artery Dis. 2013;24(1):61-68.
- Kereiakes DJ, Cannon LA, Dauber I, et al. Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results. Catheter Cardiovasc Interv. 2015;86(6):994-1001.
- Yamaji K, Raber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37(45):3386-3395.
- Data from Eluvia, Zilver PTX, Lutonix, Stellarex and IN.PACT DFUs.
- Data on file at Boston Scientific.
- Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.
- Data on file at Boston Scientific. Represents total population of patients studied in the PROMUS and XIENCE series of clinical trials.